Page 2424 - Williams Hematology ( PDFDrive )

2395
2394 Index Index 2395

trisomy 8, 1384t morphological variants, 1282–1283, 1283f, histone deacetylase inhibitors, 219,
trisomy 11, 181 1387–1393, 1388–1389t 240
chromosome markers, 1377 acute basophilic leukemia, 1393 immunotherapy and antisense DNA
deregulated signaling pathways, 1379 acute eosinophilic leukemia, 955t, 1392 approaches, 1404
environmental factors, 1320, 1374 acute erythroid leukemia, 608, 1382f, modulation of drug resistance, 1404
evolution from a chronic myeloid 1390 therapies targeted to signal
neoplasm, 1373–1374 acute mast cell leukemia, 1393 transduction mediators, 1403–1404
gene markers, 1376–1377 acute megakaryoblastic Wee1 inhibitors, 219
gene mutations, 181–182, 1377–1379, (megakaryocytic) leukemia, 1382f, remission-induction therapy,
1378t 1392 1394–1398
ASXL1, 226t acute monocytic leukemia, 181, 1096, cytotoxic regimens, 1394–1396, 1395t
CEBPA, 181, 181t, 182, 226t, 363, 1382f, 1391–1392 principles, 1394
1378t, 1379 acute myeloblastic leukemia, 1382f, 1387 special considerations, 1396–1398
DNMT3A, 226t, 1377–1378, 1378t acute myelomonocytic leukemia, 180, special considerations
FLT3, 181, 181t, 198, 226t, 363, 1377, 1382f, 1387, 1390 in acute promyelocytic leukemia,
1378t, 1383, 1415 acute promyelocytic leukemia. See Acute 1404–1407, 1405t
frequency, 181t, 1308f promyelocytic leukemia (APL) in children, 1409–1410
hematopoietic cell transplantation myelodysplastic syndromes and, 178, 181 in older patients, 1408–1409
response and, 363 neonatal myeloproliferative syndromes in Ph-chromosome-positive AML,
IDH1/2, 226t, 1378t, 1379 and, 1385–1386 1407
KIT, 181, 181t, 227t, 1376 oligoblastic, 1384–1385 in pregnant patients, 1409
MLL-PTD, 226t, 1378t pathogenesis, 1281–1282, 1281f in secondary acute myelogenous
NPM1, 181, 226t, 363, 1377, 1378t Philadelphia-chromosome–positive, 1385, leukemia, 1407
NRAS, 227t, 1376, 1378t, 1386 1407 Acute myelomonocytic leukemia (AMML),
PHF6, 227t during pregnancy, 124 180, 1382f, 1387, 1388t, 1390
prognosis and, 181, 1413–1414t progenitor cell leukemia and, 1283 Acute myocardial infarction. See Myocardial
RUNX1 (AML1), 181t, 226t, 237, secondary, 1407 infarction (MI)
1351, 1376, 1378, 1378t, 1384t, therapy-related, 177f, 179t, 182–183, 182f, Acute-phase response, 284–285
1415, 2060 1520 Acute porphyrias, 889
somatic, 1376 treatment, 1393–1411 Acute promyelocytic leukemia (APL),
TET2, 226t, 1378–1379, 1378t decision to treat, 1393–1394 1390–1391
TP53, 227t leukocytapheresis, 433 chromosomal abnormalities, 177f, 181,
WT1, 227t, 1378t, 1379 nonhematopoietic adverse effects, 1390–1391
mode of inheritance, 1379 1410–1411 clinical features, 1388t, 1390
molecular pathogenesis, 1376 overview, 1393 disseminated intravascular coagulation
predisposing diseases, 1374t, 1375 patient preparation, 1394 and, 2208
familial platelet disorder with postremission therapy, 1398–1401 epidemiology, 1390
predisposition to, 2060 autologous stem cell infusion, 1399 laboratory features, 1382f, 1388t, 1391
hybrid, 1386 cytotoxic therapy, 1398–1399 long-term survival, 1412
hypoplastic, 1384 donor leukocyte infusion, 1400–1401 treatment, 1391, 1404–1407, 2317t, 2318
immunologic phenotypes, 1380t hematopoietic cell transplantation, Acute respiratory distress syndrome (ARDS),
laboratory features, 1381–1387 363–364, 1398, 1399–1400 2201, 2204–2205, 2208
basophilia, 972, 972t recurrent leukemia in donor cells, ACVRP regimen, for diffuse large B-cell
blood, 1381, 1382f 1401 lymphoma, 1628
cytogenetic abnormalities, 1383, in relapsed or refractory disease ACY-1215, 1754
1384t antiangiogenesis agents/agents Acyclovir
eosinophilia, 955t that inhibit microenvironmental as empiric therapy for infections, 386, 387t
hyperleukocytosis, 1384 interactions, 1404 for Epstein-Barr virus infection, 1269
hypoplastic leukemia, 1384 CD33 antibodies, 1403 for HSV infection, 370
lymphocytosis, 1204 chemotherapy, 1401, 1402t megaloblastic anemia and, 606t
marrow, 1381–1383, 1382f cyclin-dependent kinase inhibitors, prophylactic, 369, 389
plasma chemical, 1383 218 ADA. See Adenosine deaminase (ADA)
mediastinal germ cell tumors and, DOT1L inhibitors, 1403 ADAM17 (TACE), 1144, 1874
1377–1388 epigenetic modulation, 1403 ADAMTS-13 (ADAMTS13)
mixed, 1386 hematopoietic cell transplantation, acquired deficiency, 2256
monocytosis and, 1096 363–364, 1400, 1402 congenital deficiency, 2257–2258

Kaushansky_index_p2393-2506.indd 2395 9/21/15 3:21 PM